Trial reportIndian journal of pharmacology2025
Effect of dexmedetomidine combined with ropivacaine in ultrasound-guided paravertebral nerve block for acute herpes zoster neuralgia patients.
Trial report in Indian journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEarly and effective treatment of acute herpes zoster (AHZ) can relief the pain and prevent the occurrence of postherpetic neuralgia (PHN) in patients. The aim of this study is to investigate the efficacy of dexmedetomidine combined with ropivacaine in ultrasound-guided paravertebral nerve block for patients with AHZ neuralgia. MATERIALS AND
methodsSeventy-four patients suffering from acute thoracic herpes zoster neuralgia were divided into two equal groups in a prospective, randomized, double-blind controlled manner. All patients received paravertebral nerve block under ultrasound guidance with different drugs: Group I: 0.2% ropivacaine with 1 μg/kg dexmedetomidine; Group II: 0.2% ropivacaine, all drugs were diluted with normal saline to a total of 20 ml. The patients' Visual Analog Scale (VAS) scores were used for assessing pain level while the quality of sleep (QS) scores were used for assessing sleep levels 1, 4, 8, and 12 weeks after the treatment, as well as the pregabalin consumption. Time to pain resolution and skin eruption, total times of block, complications within 24 h after block, and the incidence of persistent PHN at 3 and 6 months were analyzed.
resultsThere were no significant differences in the VAS scores between the two groups at various time points (P > 0.05). At the time point 1, 4, and 8 weeks after treatment, the QS scores in Group I were significantly lower than that in Group II (P < 0.05). The pregabalin consumption and the incidence of PHN between the two groups were not significantly different (P > 0.05). The total times of block in Group I were significantly less than Group II.
conclusionBoth interventions provided similar efficacy in minimizing the pain intensity and reducing the incidence of PHN in AHZ patients. Compared with ropivacaine only, the addition of dexmedetomidine significantly improved patients' sleep quality and reduced the times of block.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.